H.C. Wainwright downgraded BeyondSpring (NASDAQ:BYSI) to “neutral” from “buy” and removed its price target, citing a change to the company’s risk profile. The stock closed at $10.80 on April 1. On March 31, BeyondSpring...
IntelGenx (TSXV:IGX; OTCQB:IGXT) completed its first shipment, consisting of 75,000 CBD filmstrips, to Heritage Cannabis Holdings (CSE:CANN) for the Canadian and Australian markets. The CBD filmstrips were produced at...
Alliance Global Partners reduced its price target for EyeGate Pharmaceuticals (NASDAQ:EYEG) to $10.25 from $16.75, citing a possible plan to sell additional common shares in the first half of this year in order to...
Cantor Fitzgerald launched coverage of Lineage Cell Therapeutics (NYSE American: LCTX) with an “overweight” rating and 12-month price target of $6. The stock closed at $2.26 on March 30. Lineage is an allogeneic cell...
Maxim Group launched coverage of Amryt Pharma plc (NASDAQ, AIM:AMYT) with a “buy” rating and $27 price target. The stock closed at $13.84 on March 30. Amryt is a commercial rare disease company globally marketing...
Echelon Capital Markets initiated coverage of CareRx (TSX:CRRX) with a “buy” rating and price target of $7.25 (Canadian). The stock closed at $5.39 on March 29. CareRx is Canada’s leading pharmacy services provider for...
Cantor Fitzgerald initiated coverage of PAVmed (NASDAQ:PAVM) with an “overweight” rating and price target of $8. The stock closed at $3.93 on March 29. The company employs a unique business model that emphasizes capital...
Cantor Fitzgerald launched coverage of Aytu BioPharma (NASDAQ:AYTU) with an “overweight” rating and $11 price target. The stock closed at $7.49 on March 29. “Through a strategy of in-licensing and acquisition-based...
Leede Jones Gable initiated coverage of Perimeter Medical Imaging (TSXV:PINK) with a “speculative buy” rating and price target of $6.75 (Canadian). The stock closed at $4.30 on March 26. The firm’s lead medical device...
Maxim Group downgraded Co-Diagnostics (NASDAQ:CODX) to “hold” from “buy” and removed its priced target, citing COVID-19 testing and revenue growth, which appear “to have peaked.” The stock closed at $9.70 on March 26...
Leede Jones Gable initiated coverage of Cardiol Therapeutics (TSX:CRDL) with a “speculative buy” rating and price target of $12.50 (Canadian). The stock closed at $4.51 on March 24. Analyst Doug Loe, Ph.D., writes that...
111, Inc. (NASDAQ:YI), a leading digital healthcare platform company in China, and Jianming Pharmaceutical Group signed a strategic cooperation agreement to develop an online chronic disease management platform for the...
Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.